|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Salix_Pharmaceuticals
gptkb:Bausch_+_Lomb
gptkb:Dendreon
|
|
gptkbp:ceo
|
gptkb:Joseph_C._Papa
2016-present
|
|
gptkbp:controversy
|
price gouging
|
|
gptkbp:employees
|
approximately 20,000
|
|
gptkbp:founded
|
gptkb:1960
|
|
gptkbp:founder
|
gptkb:M._S._(Mike)_Mc_Gowan
|
|
gptkbp:headquarters
|
gptkb:Laval,_Quebec,_Canada
gptkb:Laval,_Quebec
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Valeant Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:market_cap
|
$8.5 billion (2021)
|
|
gptkbp:notable_products
|
gptkb:Aldara
gptkb:Vigamox
gptkb:Xalatan
gptkb:Arestin
gptkb:Systane
gptkb:Bepreve
gptkb:Acanya
gptkb:Alphagan
gptkb:Bausch_+_Lomb_contact_lenses
gptkb:Ciprodex
gptkb:Duo_Neb
gptkb:Durezol
gptkb:Jublia
gptkb:Lotemax
gptkb:Pataday
gptkb:Protopic
gptkb:Restasis
gptkb:Retin-A
gptkb:Systane_Ultra
gptkb:Tobradex
gptkb:Vesicare
gptkb:Vyzulta
gptkb:Xifaxan
gptkb:Zymar
gptkb:Zymaxid
gptkb:Lumify
gptkb:Cera_Ve
Ocuvite
Siliq
Similasan
|
|
gptkbp:products
|
generic pharmaceuticals
branded pharmaceuticals
|
|
gptkbp:revenue
|
$8.4 billion (2015)
|
|
gptkbp:stock_exchange
|
gptkb:NYSE
|
|
gptkbp:stock_symbol
|
VRX
|
|
gptkbp:subsidiary
|
gptkb:Bausch_Health_Companies_Inc.
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.valeant.com
|
|
gptkbp:bfsParent
|
gptkb:Bausch_&_Lomb
|
|
gptkbp:bfsLayer
|
5
|